The ESS system is designed to stimulate progenitor stem cells in the bone marrow

Kiadis Pharma BV, of Amsterdam, the Netherlands, said it received a No Objection Letter from Canadian regulators to proceed with a Phase II study testing ATIR, a cell-based product designed to enable stem cell transplantation from mismatched family donors

Chimerix Inc., of Research Triangle Park, N.C., presented data during the Allogeneic Transplants Poster Session at the BMT Tandem Meetings in Salt Lake City over the weekend, including data from a Phase II study testing CMX001 for the prevention of cytomegalovirus infection following allogeneic hematopoietic stem cell transplantation

CDX-301 is a cytokine that stimulates the expansion and differentiation of hematopoietic progenitor and stem cells...Gamida Cell Ltd., of Jerusalem, disclosed results of the Phase I/II study of its second pipeline product NiCord, umbilical cord derived stem cells expanded using the company's NAM technology

Steven Schwartz, professor of ophthalmology at the David Geffen School of Medicine at UCLA and retina division chief at UCLA's Jules Stein Eye Institute, plans to lead a Phase I/II study using ACT's retinal pigment epithelial (RPE) cells, derived from human embryonic stem cells (hESC), to treat myopic macular degeneration, commonly known as nearsightedness

Ltd., of Seoul, South Korea, said it filed an investigational new drug application with Korean regulators to start Phase II and Phase III studies testing its RNL-Astrostem stem cell drug in patients with cerebral palsy...Data from a Phase I trial showed that the product, an intravenous infusion of human adipose tissue-derived mesenchymal stem cells, suggested potential efficacy in the disease

The dose-escalation study will evaluate safety, tolerability and efficacy as determined by RECIST criteria and the company's cancer stem cell biomarkers

BrainStorm Cell Therapeutics Inc., of New York, began treating its first patient in a Phase IIa trial of its stem cell therapy in amyotrophic lateral sclerosis

ImmunoCellular Therapeutics Ltd., of Los Angeles, said the FDA allowed the investigational new drug application for ICT-140, a dendritic cell vaccine targeting seven antigens that are overexpressed in ovarian cancer as well as cancer stem cells

Spectrum Pharmaceuticals Inc., of Henderson, Nev., said data from the BELIEF trial showed belinostat had an acceptable safety profile in patients with relapsed/refractory peripheral T-cell lymphoma, including those who received a previous allogeneic or autologous stem cell transplant

The primary objective is to determine the safety and toxicity of human spinal stem cell transplantation for the treatment of paralysis and related symptoms due to chronic spinal cord injury (SCI...The trial also will look at exploratory objectives to evaluate the ability of human spinal cord stem cell transplantation to positively affect AIS level, ISNC SCI motor and sensory index scores, bowel and bladder function, pain, UAB IMR scores, SCIM scores, evoked sensory and motor potentials and

BioTime Inc., of Alameda, Calif., said it submitted a clinical investigation protocol to European regulatory authorities for approval to initiate studies for its Renevia stem cell delivery platform

Advanced Cell Technology Inc., of Marlborough, Mass., reported evidence of engraftment of transplanted human embryonic stem cell-derived retinal pigment epithelial cells and visual acuity gain in a Phase I/II trial in Stargardt's macular dystrophy (SMD) and dry age-related macular degeneration (AMD

The study will evaluate the safety and preliminary efficacy of the firm's NurOwn stem cell therapy candidate

Advanced Cell Technology Inc., of Marlborough, Mass., treated the fifth and sixth patients in its European trial for Stargardt's macular dystrophy using retinal pigment epithelial cells derived from human embryonic stem cells

Data were provided in an oral presentation that updated results of a large prospective study on the use of defibrotide in the treatment of hepatic veno-occlusive disease in hematopoietic stem cell transplant patients, from the ongoing treatment investigational new drug application expanded-access protocol...The interim analysis was based on 333 patients with severe veno-occlusive disease and multi-organ failure, enrolled between December 2007 and September 2011, in which 305 patients had undergone

Neuralstem Inc., of Rockville, Md., presented Phase I data at the International Symposium on ALS/MND in Chicago from its spinal cord transplantation of neural progenitor cells in patients with amyotrophic lateral sclerosis, showing that researchers were able to establish the long-term survival of the transplanted spinal cord stem cells in autopsied patients

with experience and expertise in stem cell clinical trials studying treatments for cardiovascular heart diseases...A further nine patients are expected to be enrolled at three oncological centers in the U.S. Based on the results, the company will implement a clinical study aimed at evaluating the effects of Reparixin, an inhibitor of the CXCR1 receptor activated by chemokine interleukin 8, in oral monotherapy on cancer stem cells and on tumor microenvironment for the treatment of women with early

trials testing retinal pigment epithelial cells derived from human embryonic stem cells